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Uremia causes endothelial progenitor cell deficiency
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Uremia causes endothelial progenitor cell deficiency.
Background. Circulating bone marrow–derived endothelial
progenitor cells (EPCs) promote vascular repair. Their number
in peripheral blood correlates with endothelial function and
cardiovascular risk in humans. We explored whether uremia
influences the number of EPCs.
Methods. We assessed circulating CD34+ hematopoietic pro-
genitor cells in whole blood using flow cytometry and EPCs (in
vitro assay) in 46 patients with advanced renal failure and in 46
age- and gender-matched healthy subjects. Further, the effect
of uremia on EPC differentiation was studied in vitro and in
vivo.
Results. Both in renal patients (r = 0.34, P < 0.02) and in
healthy subjects (r = 0.32, P = 0.04) the number of EPCs
was significantly correlated to the absolute number of CD34+
hematopoietic progenitor cells. Renal patients had significantly
fewer EPCs than healthy subjects, however (167 ± 15 cells/high
power field vs. 235 ± 17 cells/high power field; P < 0.05). Ure-
mic serum significantly (P < 0.05) inhibited EPC differentiation
and functional activity in vitro. Amelioration of uremia after in-
stitution of renal replacement therapy in patients with terminal
renal failure also significantly (P < 0.05) increased the number
of EPCs.
Conclusion. Uremia inhibits differentiation of EPCs. This
may impair cardiovascular repair mechanisms in patients with
renal failure.
Patients with renal failure are characterized by high
cardiovascular morbidity and mortality, and most die of
complications related to atherosclerosis, namely myocar-
dial infarction and stroke [1]. Several traditional and non-
traditional cardiovascular risk factors are thought to play
a certain role, but the idea that impaired vascular re-
pair mechanisms may contribute to the problem has not
been pursued so far. In this respect current research has
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focused on bone marrow–derived endothelial progeni-
tor cells (EPCs), because these cells mediate reparative
processes in the cardiovascular system [2–4]. EPCs are
considered to originate from CD34+ hematopoietic stem
cells, which differentiate via separate pathways into ery-
throcytes, thrombocytes, various lineages of leukocytes,
and endothelial cells. EPCs circulate in the vasculature
where they home and incorporate into sites of active neo-
vascularization [5, 6]. In patients with coronary artery
disease the number of EPCs correlates strongly with the
number of cardiovascular risk factors [7]. This correlation
exists even in subjects without manifest atherosclerosis.
In the latter population the number of EPCs also corre-
lates with the degree of endothelial dysfunction [8].
We could recently demonstrate that administration of
recombinant human erythropoietin (rhEPO) or its ana-
logue darbepoetin enhances EPC differentiation in vitro
and in vivo [9, 10]. Furthermore, in laboratory animals
rhEPO causes a significant mobilization of EPCs from
the bone marrow [11]. Thus, a reduced number and/or
impaired function of EPCs due to EPO deficiency could
be a potential cardiovascular risk factor contributing to
morbidity and mortality in patients with advanced renal
failure. In the present study we therefore tested the hy-
pothesis that the number EPCs is reduced in uremia. For
this purpose we assessed EPCs in uremic patients and in
age- and gender-matched control subjects. In addition,
we studied patients with end-stage renal disease (ESRD)
who started renal replacement therapy but did not yet re-
quire rhEPO. Finally, we cultivated EPCs in the presence
of serum from uremic and healthy subjects.
METHODS
Participants and protocol
The study protocol was approved by the Hannover
Medical School Ethics Committee. We assessed the num-
ber EPCs in patients with advanced renal failure and in
age- and gender-matched control subjects after obtain-
ing informed consent (Table 1). Patients with concomi-
tant chronic inflammatory diseases or clinically manifest
acute infections, malignant diseases, manifest or occult
bleeding conditions, or recent cardiovascular events were
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Table 1. Clinical and laboratory data of patients with advanced renal
failure and age- and gender-matched healthy subjects
Renal patients Controls
Number 46 46
Age years 58.6 ± 2.51 57.5 ± 2.0
Gender male/female 29/17 29/17
Serum creatinine mg/dL 5.67 ± 0.39 0.89 ± 0.02a
CD34+ hematopoietic progenitor 1.62 ± 0.19 2.09 ± 0.19
cells per lL
Endothelial progenitor cells 167 ± 15 235 ± 17a
per high power field
Haematocrit % 31.9 ± 0.79 43.4 ± 0.54a
Erythropoietin U/L 8.6 ± 0.56 12.9 ± 0.46a
High sensitive C-reactive protein mg/L 6.2 ± 1.18 2.5 ± 0.54a
White blood cell count 103/lL 8.0 ± 0.3 6.2 ± 0.3a
Lymphocyte count % of white 16.8 ± 1.2 29.6 ± 0.9a
blood cells
Monocyte count % of white blood cells 7.5 ± 0.4 7.4 ± 0.3
aP < 0.05 comparison between renal patients and healthy controls.
excluded from the study. None of the patients received a
therapy with rhEPO or analogues, and blood transfusions
were not administered for at least 3 months before study
entry. In addition, we studied six patients with ESRD (five
males and one female, aged 58.4 ± 9.0 years) who started
renal replacement therapy, but did not yet require rhEPO
treatment nor blood transfusion before and during the
first 2 weeks of hemodialysis. We assessed the absolute
number of EPCs and CD34+ hematopoietic progenitor
cells (HPCs) in these patients before and after 2 weeks
of treatment. All routine laboratory measurements were
done using certified assay methods.
Flow cytometry of circulating HPCs
In all participants we analyzed the total number of cir-
culating HPCs using flow cytometry (Epics XL Cytome-
ter; Coulter Beckman, Krefeld, Germany). We adopted
a gating strategy for flow cytometry on the basis of
the International Society of Hematotherapy and Graft
Engineering (ISHAGE) guidelines, and used the CD34
and CD45 expression patterns as well as the morpho-
logic qualities of progenitor cells for their detection
(Fig. 1) [12]. For this purpose we stained whole ethylene-
diaminetetraacetic acid (EDTA) blood within 6 hours
after drawing the blood. Thereafter, we incubated a vol-
ume of 100 lL with an appropriate amount of fluores-
cein isothiocyanate (FITC)-labeled monoclonal mouse
antihuman-CD45 antibody (Coulter Beckman) for 20
minutes. For detection of HPCs we added phycoerythrin-
labeled monoclonal mouse ant-human-CD34 antibody
(Coulter Beckman) to the sample after titration of the
optimal antibody concentration. In addition, we added
a phycoerythrin-labeled mouse IgG1-antibody (Coulter
Beckman) to a second anti-CD45 stained blood sample
as the isotype control. Subsequent lysis was done with
ammonium chloride, and at least 200,000 CD45+ cells
were acquired. Two blinded investigators independently
assessed the number of HPCs. Day-to-day variability of
the absolute HPC number was below 12% as assessed
by flow cytometry of HPCs in eight healthy subjects on
four consecutive days. Interassay variability (N = 10) was
below 5%.
Isolation of EPCs
We isolated peripheral blood mononuclear cells from
14 mL blood in order to cultivate EPCs as described
elsewhere [2, 13, 14]. We used density gradient cen-
trifugation with Bicoll (Biochrome, Berlin, Germany),
and seeded 107 cells on 6-well plates coated with hu-
man fibronectin (Sigma Chemical Co., St. Louis, MO,
USA) in endothelial basal medium (EBM-2) (Clonetics,
Walkersville, MD, USA). The medium was supple-
mented with endothelial growth medium-2 (EGM-2) Sin-
gle Quots containing fetal bovine serum (FBS), human
vascular endothelial growth factor (VEGF-A), human
fibroblast growth factor-B(FGF-B), human epidermal
growth factor (EGF), insulin-like growth factor-1 (IGF-
1), and ascorbic acid in appropriate amounts. After 4 days
in culture, we removed nonadherent cells by washing the
plates with phosphate-buffered saline (PBS). We trypsi-
nated the remaining adherent cells and reseeded 106 cells
on fibronectin-coated 6-well plates. New media was ap-
plied and the cell culture was maintained through day
7. We further performed fluorescent chemical detection
in order to determine the cell type of the attached hu-
man peripheral blood mononuclear cells after 7 days in
culture. To detect the uptake of 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine–labeled acetylated low-
density lipoprotein (acLDL-DiI) (Molecular Probes,
Eugene, OR, USA), we incubated the cells with acLDL-
DiI (6 lg/mL) at 37◦C for 2 hours. Cells were then fixed
with 1% paraformaldehyde for 10 minutes and incubated
with FITC-labeled Ulex europaeus agglutinin-1 (UEA-
1) (Sigma) for 1 hour. After the staining, we viewed the
samples with an inverted fluorescent microscope (Leica,
Wetzlar, Germany). We counted double stained cells for
both UEA-1 and acLDL-DiI as EPCs. Two blinded in-
vestigators counted at least four randomly selected high
power fields. Using such a protocol we also cultivated
EPCs from eight healthy subjects in four experiments in
the presence of uremic and normal serum.
Functional studies on EPCs
We studied functional activity of EPCs using a tube
formation assay as described previously [15]. Briefly, DiI-
labeled EPCs obtained from eight healthy volunteers
were co-plated with human umbilical vein endothelial
cells (HUVECs) on a 4-well glass slide precoated with 250
lL of ECMatrixTM (Chemicon International, Hofheim,
Germany) in 500 lL EGM-2 with a 10% addition of
serum from a healthy and a uremic person, respectively.
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Fig. 1. Gating strategy for detection of circulating hematopoietic progenitor cells (HPCs) on the basis of the International Society of Hematotherapy
and Graft Engineering (ISHAGE) guidelines. We used CD34 and CD45 expression as well as the morphologic qualities of HPCs for their detection.
The upper panels (A, B, C, and D) represent a patient sample stained with anti-CD45 fluorescein isothiocyanate (FITC) and anti-CD34 polyethylene
(PE). The lower panels (E, F, G, and H) show the same sample using an isotype control for anti-CD34. We first counted 200,000 CD45+ cells (A
and E). From this primary gate, HPCs were identified using the additional expression of CD34 (B and F). The CD45 antigen expression (C and G)
and the characteristic light scatter properties (D and H) are shown.
After 4 hours of incubation in 5% CO2 humidified atmo-
sphere at 37◦C, the three-dimensional organization of the
cells was examined under an inverted phase-contrast pho-
tomicroscope using following grades: 0, individual cells,
well separated; 1, cells begin to migrate and align them-
selves; 2, capillary tubes visible, no sprouting; 3, sprouting
of new capillary tubes visible; 4, closed polygons begin
to form; and 5, complex mesh-like structures develop. A
blinded investigator examined at least ten randomly se-
lected high power fields.
Further, we performed a Transwell migration assay in
order to study EPC migration. The migratory capacity of
EPCs was assessed by their ability to cross the 8 lm pores
of migration chambers represented by transwells fitted
with polycarbonate membranes (10 mm filters, 8 lm pore
size) (Nunc A/S, Roskilde, Denmark). For this purpose
5 × 105 day 7 EPCs of eight healthy volunteers, previ-
ously starved for 24 hours, were plated in the upper wells
of transwell chambers containing either EGM-2 with a
10% addition of serum from a healthy or a uremic per-
son. The migration apparatus was assembled and incu-
bated for 6 hours in a humidified environment (5% CO2)
at 37◦C. After incubation, the upper wells of the migra-
tion chamber were removed, and the migrated cells were
counted by flow cytometry.
Statistical analysis
We compared baseline characteristics of patients with
renal failure and control subjects using a v 2 test for cat-
egorical variables and an unpaired t test for continuous
variables (SPSS, version 10.0.7 for Windows; Chicago, IL,
USA). Results were corrected for multiple comparisons.
The statistical significance was set at P < 0.05. Data are
shown as mean ± SEM. Further, in both groups we per-
formed Pearson’s correlation analysis between the num-
bers of EPCs, on the one hand, and age, the number
of CD34+ HPCs, and blood hematocrit, EPO, and high
sensitive C-reactive protein (hsCRP) levels on the other
hand. In addition, independent predictors of EPC num-
ber were evaluated using a stepwise multiple regression
analysis with combined data of renal patients and healthy
subjects. The difference in EPC number in patients with
ESRD before and after renal replacement therapy was
analyzed using a Mann-Whitney U test, and data obtained
in in vitro experiments were compared using a t test for
random data.
RESULTS
Patients with advanced renal failure and healthy con-
trols were well matched with respect to age and gender
(Table 1). Renal patients had significantly fewer EPCs
per high power field than healthy subjects, however. In-
dividual data on the total number of EPCs are shown in
Figure 2. Cell culture plates from a representative patient
and a matched control subject are shown in Figure 3 (up-
per panel). The absolute number of circulating CD34+
HPCs was lower in renal patients as well, but the differ-
ence was not significant. In addition, renal patients had
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Fig. 2. Box Plots of endothelial progenitor cells (EPCs) and plasma
erythropoietin (EPO) levels in 46 patients with advanced renal failure
and in 46 age- and gender-matched healthy subjects. The differences
between groups for both parameters were significant (P < 0.05).
significantly lower blood EPO concentrations (Fig. 2) and
significantly higher hsCRP levels.
In patients with advanced renal failure the number of
EPCs did not correlate with age (r = 0.11, P = 0.46),
hematocrit (r = 0.10, P = 0.49), or blood EPO (r = 0.06,
P = 0.73), and hsCRP (r = −0.07, P = 0.64) concentra-
tions. In contrast, the correlation between EPCs and the
absolute number of CD34+ HPCs was significant (r =
0.34, P < 0.02). In healthy subjects this correlation was
significant (r = 0.32, P < 0.04) as well, whereas EPC num-
ber did not correlate with age (r =−0.20, P = 0.19), hema-
tocrit (r = −0.19, P = 0.20), or blood EPO (r = 0.10, P =
0.54), and hsCRP (r = −0.05, P = 0.75) concentrations.
The stepwise multiple regression analysis revealed that
the absolute number of CD34+ HPCs (r = 0.31; P <
0.004) and plasma EPO levels (r = 0.22; P < 0.041) were
independent predictors of the total number of EPCs in
our study cohort.
In patients with ESRD the number of EPCs increased
significantly (P < 0.05) from 187 ± 45 cells/high power
field to 275 ± 30 cells/high power field after institution
of renal replacement therapy. The number of CD34+
HPCs increased as well, but the difference did not reach
statistical significance (1.75 ± 0.29 vs. 1.92 ± 0.31, NS).
In contrast, the hematocrit level remained unchanged
(33.4 ± 2.6 vs. 32.9 ± 2.3; NS).
As shown in Figure 3 (lower panel) serum from uremic
patients significantly (110 ± 14 vs. 168 ± 28, P < 0.05)
inhibited EPC differentiation in vitro in comparison to
serum from healthy individuals. Further, the ability of
EPCs to contribute to tube formation was significantly re-
duced in uremic patients as compared to healthy subjects
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Fig. 3. Representative images of cultured endothelial progenitor cells
(EPCs). EPCs in a uremic patient (left upper panel) and an age- and
gender-matched healthy subject (right upper panel) are shown. EPCs af-
ter 7 days in culture supplemented with uremic serum (left lower panel)
and normal serum (right lower panel). The graph below presents mean
EPC numbers in culture from eight healthy subjects supplemented with
serum from uremic patients and healthy subjects, respectively.
(tube formation index: uremic serum 3.7 ± 0.2, healthy
serum: 4.3 ± 0.2; P < 0.05). Finally, the migration capacity
of EPC cultured in the presence of uremic serum was re-
duced to 72% of the migration capacity of EPCs cultured
in the presence of serum obtained from healthy subjects.
DISCUSSION
The results of the present study document that the
number of EPCs is significantly reduced in patients with
advanced renal failure as compared with age- and gender-
matched healthy subjects. In addition, we found a signif-
icant correlation between CD34+ HPCs and EPCs both
in healthy subjects as well as in renal patients. Taken to-
gether, these findings point to a problem of differentia-
tion of precursor cells to EPCs or to reduced mobilization
of EPCs from the bone marrow, or both, in uremia. The
former assumption is supported by the observation of a
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significant inhibitory effect of uremic serum on the differ-
entiation capacity of EPCs in vitro. However, we cannot
rule out the possibility that uremia hampers the attach-
ment of EPCs to the extracellular matrix (fibronectin).
Furthermore, functional properties such as the capability
of EPCs to migrate and to form tube-like structures were
impaired. In addition, a significant increase in the number
of EPCs goes in parallel with amelioration of uremia after
institution of renal replacement therapy in patients with
terminal renal failure. We have studied a relatively small
number of patients with ESRD, as it is difficult to find
patients in the terminal phase of their renal disease with
stable hematocrit without requiring rhEPO replacement.
In order to more convincingly prove the adverse effect of
uremia on EPCs we have also explored the direct effect of
uremic serum on EPC development in vitro. The results
of these experiments confirmed the hypothesis that ure-
mia hinders EPC differentiation. The reason(s) for this
inhibitory action have to be unfolded yet, but the find-
ing is reminiscent of the well-known defects of cellular
function caused by uremic intoxication [16, 17].
One important factor contributing to EPC deficiency in
patients with advanced renal failure could be lack of EPO,
because we could recently demonstrate that administra-
tion of rhEPO to renal patients and to healthy subjects
stimulates EPCs in vitro and in vivo via the AKT pathway.
Furthermore, we and others were able to demonstrate
that EPO directly enhances EPC mobilization from the
bone marrow [10, 11]. Hence, one would expect that EPC
numbers are, at least in part, correlated to EPO blood lev-
els. EPCs in uremic patients were not correlated to EPO
blood levels, and the same was true also for healthy sub-
jects. This finding is contradictory only at the first glance.
In the regression analysis independent predictors of EPC
levels in our cohort were the number of CD34+ HPCs
and plasma EPO levels, however. Further, the dose of
rhEPO which already markedly stimulated EPCs in vivo
was below that required to achieve a significant increase
in hematocrit levels. Thus, it is conceivable that EPC num-
ber and the number of red blood cells are regulated by
independent mechanisms and/or at different EPO blood
concentrations. Patients examined in the present study
had all advanced renal failure and uniformly low EPO
blood concentrations. Studies exploring the relationship
between blood EPO levels and EPCs in patients at dif-
ferent stages of renal failure will clarify this issue.
In addition to EPO deficiency, a number of cardiovas-
cular risk factors are known to be present in uremic pa-
tients, which all theoretically can influence EPC number
and function (e.g., dyslipidemia and hypertension) [7, 8,
18]. It is almost impossible to clearly distinguish the im-
pact of these factors singularly on EPCs in renal patients,
however. EPCs have come into focus of cardiovascular
research recently, because they govern endothelial and
hence vascular repair [2–4]. This has been shown in sev-
eral experimental studies using different animal models
of cardiovascular injury [6, 19, 20]. Even more intrigu-
ing were data obtained in human studies, showing that
the number of circulating EPCs predicts outcome after
myocardial infarction. Thus, studies exploring such a re-
lationship are warranted also in renal patients (i.e., a pop-
ulation characterized by high cardiovascular morbidity
and mortality due to vascular complications) [1].
CONCLUSION
Differentiation of EPCs is inhibited in uremia. This
may impair cardiovascular repair mechanisms in patients
with renal failure. Since EPO stimulates EPCs, treatment
with rhEPO might be indicated at an earlier stage of renal
failure as currently recommended.
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